Safety and efficacy of non-vitamin K antagonist oral anticoagulants for prevention of thromboembolism in adults with systemic right ventricle: Results from the NOTE international registry

Scognamiglio, Giancarlo; Fusco, Flavia; Hankel, Tara C.; Bouma, Berto J.; Greutmann, Matthias; Khairy, Paul; Ladouceur, Magalie; Dimopoulos, Konstantinos; Niwa, Koichiro; Broberg, Craig S.; Miranda, Berta; Budts, Werner; Bouchardy, Judith; Schwerzmann, Markus; Lipczyńska, Magdalena; Tobler, Daniel; Tsai, Shane; Egbe, Alexander C.; Aboulhosn, Jamil; Fernandes, Susan M.; Garr, BreAnn; Rutz, Tobias; Mizuno, Atsushi; Proietti, Anna Bárbara de Freitas Carneiro; Alonso‐Gonzalez, Rafael; Mulder, Barbara J.M.; Sarubbi, Berardo

doi:10.1016/j.ijcard.2020.08.034

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of DOAC therapy has seen it become the OAC agent of choice for most anticoagulation indications which has raised questions regarding its applicability in the treatment of sRV thrombus in the setting of the limited data. The international NOTE registry evaluated 530 adults with congenital heart disease treated with OAC for various indications and concluded non-inferior efficacy and safety of DOAC use compared to VKA; subgroup analysis of 76 patients with sRV found high efficacy and safety rates[ 33 , 34 ]. Another similar study of 215 patients with different congenital heart diseases quoted high efficacy rates but non-negligible bleeding risks[ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Systemic right ventricle complications in levo-transposition of the great arteries: A case report and review of literature

Almajed,

Khan

et al. 2023

World J Cardiol

View full text Add to dashboard Cite

The rise in incidence rates of invasive candidiasis warrants an increase in attention and efforts toward preventing and treating this virulent infection. Cardiac involvement is one of the most feared sequelae and has a poor prognosis. Despite the introduction of several novel antifungal agents over the past quarter century, complications and mortality rates due to Candida endocarditis have remained high. Although fungal endocarditis has a mechanism similar to bacterial endocarditis, no specific diagnostic criteria or algorithm exists to help guide its management. Furthermore, recent data has questioned the current guidelines recommending a combined approach of antifungal agents with surgical valve or indwelling prostheses removal. With the emergence of multidrug-resistant Candida auris , a focus on improved prophylactic measures and management strategies is necessary.

show abstract

Section: Discussionmentioning

confidence: 99%